Merck will gain the exclusive global license for Chinese drugmaker Hansoh’s HS-10535, an experimental oral drug that targets GLP-1 receptors. Read More
Merck snags Chinese obesity drug in nearly $2 billion deal
Estimated read time
1 min read
You May Also Like
Gold Steadies as Traders Focus on Uncertain 2025 Rate Path
December 25, 2024
European Gas Swings With One Week Left on Key Transit Deal
December 25, 2024
UK, French Stocks Rise in Thin Christmas Eve Trade; Vistry Sinks
December 25, 2024
More From Author
Nearly 30% of crypto trends focused on meme coins in 2024, survey shows
December 25, 2024
Jason Segel on Brett Goldstein, Forgiveness
December 25, 2024
Ethereum Price Approaches Critical Resistance: A Turning Point?
December 25, 2024
+ There are no comments
Add yours